what is in a glp 1 GLP-1 and Anesthesia: Considerations and Cautions for CRNAs Targeting GLP-1, GIP & GCG

Molecular mechanisms and therapeutic targets for diabetic kidney disease

Nausea is common, mostly transient, mostly mild, and concentrated during dose escalation

Pair these results with symptom tracking to stay on top of your progress and address any challenges

doi:10.1038/s41591-023-02669-x Nunn E, Jaiswal N, Gavin M, et al

In February 2025, Gan & Lee Pharmaceuticals (hereafter referred to as "Gan & Lee," stock code: 603087.SH) unveiled that the first participant was successfully dosed in a large-scale Phase 3 clinical trial (OPTIMUM-2) of Bofanglutide, a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) independently, in Chinese participant with type 2 diabetes mellitus (T2DM)

World J Hepatol 15:6878